ArticleJournal of endocrinological investigation2016
Vitamin D improves diabetic nephropathy in rats by inhibiting renin and relieving oxidative stress.
Article in Journal of endocrinological investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Bidirectional Mendelian randomization analysis of the causal associations between serum vitamin D levels and multiple kidney diseases.Scientific reports · 2025Article
- Moringa isothiocyanate-1 mitigates the damage of oxidative stress and apoptosis in diabetic nephropathy mice.Histology and histopathology · 2024Article
- The impact of vitamin D on the etiopathogenesis and the progression of type 1 and type 2 diabetes in children and adults.Frontiers in endocrinology · 2024Review
- Development and validation of short-term renal prognosis prediction model in diabetic patients with acute kidney injury.Diabetology & metabolic syndrome · 2022Article
- Correlation Between Serum 25-Hydroxyvitamin D Levels in Albuminuria Progression of Diabetic Kidney Disease and Underlying Mechanisms By Bioinformatics Analysis.Frontiers in endocrinology · 2022Article
- Changes in Metabolic Parameters in Patients with Diabetic Kidney Disease Depending on the Status of D3.Reviews on recent clinical trials · 2022Review
- Beneficial effects of vitamin D on anxiety and depression-like behaviors induced by unpredictable chronic mild stress by suppression of brain oxidative stress and neuroinflammation in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Association Between 25(OH)Vitamin D, HbA1c and Albuminuria in Diabetes Mellitus: Data From a Population-Based Study (VIDAMAZON).Frontiers in endocrinology · 2021Article
- Elevated NLRP3 Inflammasome Levels Correlate With Vitamin D in the Vitreous of Proliferative Diabetic Retinopathy.Frontiers in medicine · 2021Article
- Article
- Excessive cholecalciferol supplementation increases kidney dysfunction associated with intrarenal artery calcification in obese insulin-resistant mice.Scientific reports · 2020Article
- Autophagy and mTOR Pathways Mediate the Potential Renoprotective Effects of Vitamin D on Diabetic Nephropathy.International journal of nephrology · 2020Article
- Role of Vitamin D Status in Diabetic Patients with Renal Disease.Medicina (Kaunas, Lithuania) · 2019Review
- Vitamin D and calcium kidney stones: a review and a proposal.International urology and nephrology · 2019Review
- Association between serum 25-hydroxyvitamin D and diabetic kidney disease in Chinese patients with type 2 diabetes.PloS one · 2019Article
- Focus on 1,25-Dihydroxyvitamin D3 in the Peripheral Nervous System.Frontiers in neuroscience · 2019Review
- Vitamin D Receptor: A Novel Therapeutic Target for Kidney Diseases.Current medicinal chemistry · 2018Review
- Vitamin D and diabetes mellitus: Causal or casual association?Reviews in endocrine & metabolic disorders · 2017Review
- Albuminuria Reduction after High Dose of Vitamin D in Patients with Type 1 Diabetes Mellitus: A Pilot Study.Frontiers in endocrinology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is well established that the activation of the renin-angiotensin system (RAS) and the oxidative stress caused by hyperglycemia are major mediators of the development and progression of diabetic nephropathy (DN). Vitamin D may be important in maintaining podocyte health, preventing epithelial-to-mesenchymal transformation, and suppressing renin gene expression and inflammation, but its mechanism requires clarification. This study evaluated the specific mechanism of vitamin D to DN improvement.
methodsWe induced a rat model of diabetes with an intraperitoneal injection of streptozotocin (60 mg/kg). The streptozotocin-induced diabetic rats were fed normal chow for about 2 months to induce the DN model. The DN rats were then treated with irbesartan and/or calcitriol, administered intragastrically about 1 month.
resultsThe rats displayed the early characteristics of DN, including increased microalbuminuria, obvious hypertrophic kidney, and a markedly increased kidney weight/bodyweight ratio. Vitamin D inhibited the compensatory increase in renin expression. Malondialdehyde, which reflects oxidative stress levels, was elevated in the DN group rats and their antioxidant capacity was significantly reduced. The irbesartan and calcitriol interventions markedly improved the renal pathology and pathophysiological changes. Irbesartan combined with vitamin D (calcitriol) more effectively ameliorated DN than irbesartan alone.
conclusionsVitamin D combined with angiotensin II type 1 receptor blockers exerts a synergistic effect on the treatment of DN, not only by inhibiting renin but also by reducing oxidative stress and increasing the renal antioxidant capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.